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A Ab bs st tr ra ac ct t
Multiple Osteochondromas is an autosomal dominant disorder characterised by the presence of multiple
osteochondromas and a variety of orthopaedic deformities. Two genes causative of Multiple Osteochondromas,
Exostosin-1 (EXT1) and Exostosin-2 (EXT2), have been identified, which act as tumour suppressor genes.
Osteochondroma can progress towards its malignant counterpart, secondary peripheral chondrosarcoma and
therefore adequate follow-up of Multiple Osteochondroma patients is important in order to detect malignant
transformation early. 
This review summarizes the considerable recent basic scientific and clinical understanding resulting in a multi-
step genetic model for peripheral cartilaginous tumorigenesis. This enabled us to suggest guidelines for clinical
management  of  Multiple  Osteochondroma  patients.  When  a  patient  is  suspected  to  have  Multiple
Osteochondroma, the radiologic documentation, histology and patient history have to be carefully reviewed,
preferably by experts and if indicated for Multiple Osteochondromas, peripheral blood of the patient can be
screened for germline mutations in either EXT1 or EXT2. After the Multiple Osteochondroma diagnosis is
established and all tumours are identified, a regular follow-up including plain radiographs and base-line bone
scan are recommended.
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I In nt tr ro od du uc ct ti io on n
Osteochondroma is the most common benign
bone tumour, which occurs as sporadic (solitary) or
multiple, usually in the context of the hereditary
syndrome, Multiple Osteochondromas (MO) [1, 2].
Considerable understanding obtained through research
on  the  genetic,  pathological  and  radiologic
background of these tumours, has provided insights
into the tumorigenesis of Multiple Osteochondromas
resulting in the optimisation of clinical management,
including radiologic and mutational screening.
I In nc ci id de en nc ce e
Osteochondromas represent about 50% of all
surgically treated primary benign bone tumours [1].
Approximately 15% of the osteochondroma patients
have multiple lesions [1, 3] of which 62% have 
a positive family history [4]. 
The incidence for Multiple Osteochondromas has
been estimated at 1:50,000 in the general population
[5], with a higher prevalence in males (male:female
ratio of 1.5:1) [4, 6], which is partly due to incomplete
penetrance in females [4]. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(4) 162
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O Os st te eo oc ch ho on nd dr ro om ma a
Osteochondroma (osteocartilaginous exostosis),
according to the 2002 WHO definition, is a cartilage
capped benign bony neoplasm on the outer surface of
bones preformed by endochondral ossification [7-9].
They develop and increase in size in the first decade
of life and cease to grow at skeletal maturation or
shortly thereafter. The most common site of involvement
is the metaphyseal region of the long bones of the
limbs, like the distal femur, upper humerus, upper tibia
and fibula [1, 8]. However, osteochondromas also
occur in flat bones, in particular the ilium and scapula.
An  important  differential  diagnostic  feature  as
compared to e.g. metachondromatosis or parosteal
and periosteal osteosarcoma, is the extension of the
medullar cavity into the lesion and the continuity of the
cortex with the underlying bone. The perichondrium,
the outer layer of osteochondroma, is continuous with
the periosteum of the underlying bone.
Many osteochondromas are cauliflower shaped and
can be divided on macroscopical grounds to often long
slender pendunculated osteochondromas and flat
sessile ones.  
In the cartilage cap the chondrocytes are arranged
in a similar fashion as in the epiphyseal growth plate.
As a typical benign tumour the chondrocytes have small
single nuclei. Binucleated chondrocytes may be seen
during active growth.  
The stalk may fracture, which may result in reactive
fibroblastic proliferation and new bone formation,
erroneously leading to interpretation as the formation
of secondary sarcoma. Attached to the perichondrium
a secondary bursa may develop and simulate the
growth of the underlying tumour. This bursa is lined by
synovium and may show inflammatory changes [3].
M Mu ul lt ti ip pl le e   O Os st te eo oc ch ho on nd dr ro om ma as s
Multiple Osteochondromas (hereditary multiple
exostoses, diaphyseal aclasis) are characterised by the
presence of multiple osteochondromas [2, 4, 6, 10, 11]
the number of which can vary significantly between and
within families. Most Multiple Osteochondroma patients
also suffer from a variety of orthopaedic deformities like
shortening of the ulna with secondary bowing of the
radius (39-60%), inequality of the limbs (10-50%), varus
or valgus angulation of the knee (8-33%), deformity of
the ankle (2-54%) and disproportionately short stature
[2, 4-6, 12]. It has been a matter of debate whether
these deformities are a result of skeletal dysplasia or 
a result of local effects on the adjacent growth plate
caused by developing osteochondromas. 
No well-documented association between Multiple
Osteochondromas  and  other  non-bone  related
disorders has been described so far. 
M Ma al li ig gn na an nt t   t tr ra an ns sf fo or rm ma at ti io on n
Malignant transformation of osteochondroma is
estimated to be less than 1% in patients with solitary
lesions  and  0.5-3%  in  patients  with  Multiple
Osteochondromas [2, 7]. In 94% of the cases with
malignant  progression  a  secondary  peripheral
chondrosarcoma has developed within the cartilage
cap of an osteochondroma [13]. Secondary peripheral
chondrosarcoma is a hyaline cartilage producing
tumour and constitutes approximately 15% of all
chondrosarcomas [1, 14], which is the third most
frequent malignant bone tumour after myeloma and
osteosarcoma [15]. Increasing pain, functional disability
and/or a growing mass, specifically after maturation
of the skeleton, may indicate malignant transformation.
Radiologic features show irregular mineralisation and
increased thickness (over 2 cm) of the cartilage cap of
an osteochondroma. The cap shows lobules of hyaline
cartilage that are separated by bands of fibrous tissue
[15]. With (dynamic) contrast enhanced magnetic
resonance (MR) imaging this can be seen as septal
enhancement whereas osteochondromas only display
peripheral  enhancement.  High-grade  peripheral
chondrosarcomas are characterised by inhomogeneous
and  homogeneous  enhancement  patterns  on
gadolinium-enhanced MR images [16, 17]. 
The histological grading of chondrosarcoma is based
on nuclear size and chromasia and cellularity [18] and
is the most important predictor of clinical behaviour and
thus prognosis of patients with chondrosarcomas [15].
Chondrosarcomas secondary to osteochondromas are
usually low-grade tumours resulting in a reasonably fair
prognosis for these patients [15].
In the remaining 6% of the cases with malignant
progression tumours arise in the bony stalk of the
osteochondroma, including osteosarcomas and spindle
cell sarcomas [19-22]. 
G Ge en ne et ti ic cs s
Multiple Osteochondromas is an autosomal dominant
disorder  for  which  two  genes  have  been  isolated,
Exostosin-1 (EXT1; OMIM 133700) located at 8q24 and
Exostosin-2 (EXT2; OMIM 133701) located at 11p11-
p12 [23-25]. 44-66% of the Multiple Osteochondroma
families show linkage at the EXT1 region [26, 27],
compared to 27% for EXT2 [27]. Germline mutations of
EXT1 and  EXT2 have  been  described  in  MultipleH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(4) 163
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F Fi ig g. .   1 1. .   Specimen radiographs and histology
A pedunculated osteochondroma shown in a macroscopic whole
mount section (A A) and specimen radiograph (B B); C C, whole mount
section of a sessile osteochondroma. Note the presence of a small
cartilage cap in both osteochondromas (<0.5 cm); D D, radiograph
of the forearm of a Multiple Osteochondroma patient. Several
osteochondromas can be seen at the ends of the ulna and radius.
Note that the ulna is shortened, which caused subsequent bowing
of the radius; E E and F F, gross specimen and whole mount section
of secondary peripheral chondrosarcoma. The cartilage cap is
thicker than 2 cm and in the whole mount section the lobules are
clearly visible.
F Fi ig g. .   1 1A A
F Fi ig g. .   1 1C C
F Fi ig g. .   1 1E E
F Fi ig g. .   1 1D D
F Fi ig g. .   1 1B B
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Osteochondroma patients from Caucasian [23, 25, 28-
31] and Asian populations [32-34]. 
Most mutations (80%) found in EXT1 and EXT2 (Fig.
2) are either nonsense, frameshift or splice-site mutations
leading to premature terminations of the EXT proteins
(reviewed by Zak et al [35]). Mutations in EXT1 occur in
all parts of the gene, while mutations in EXT2 concentrate
towards the N-terminus of the gene, implying that this
part of the protein may have special functions. This seems
contradictive, since only the C-terminal region is highly
conserved, implicating some functional importance for
this part of the protein [24, 25]. In the literature, only one
somatic mutation in the EXT1 gene has been described
in a sporadic chondrosarcoma [29].
Loss of the remaining wild-type allele has been
demonstrated in hereditary osteochondromas [31],
indicating that the EXT genes act as tumour suppressor
genes in Multiple Osteochondromas. This is consistent
with Knudson’s two-hit model for tumour suppressor
genes [36]. 
Not many genotype-phenotype correlation studies
have been described to draw definitive conclusions
[37, 38]. There seems to be a slightly higher risk of
malignant transformation in patients with an EXT1
mutation as compared to EXT2 [38]. 
The existence of a third EXT gene on chromosome
19p, EXT3 [39], has been suggested, however no gene
has been identified, nor has this locus been implicated
by other researchers.
Based on their homology with EXT1 and EXT2,
three other members of the EXT-family of genes, the
EXT-like genes (EXTL1-3), have been identified [40-42].
EXTL1, EXTL2 and EXTL3 are located at 1p36.1 [40],
1p11-p12 [41] and 8p12-p22 [42], respectively. No
linkage with Multiple Osteochondromas or other bone
diseases has been documented for these genes [43].
E EX XT T1 1
Before  linkage  to  Multiple  Osteochondromas,
osteochondromas were already known to be involved
in a contiguous gene deletion syndrome, the Langer
Gideon  syndrome  (LGS  or  trichorhinophalangeal
syndrome type II; OMIM150230) [44], where patients
carry  a  deletion  of  8q24  [45].  Besides  multiple
osteochondromas the Langer Gideon syndrome is
characterised by craniofacial dysmorphism and mental
retardation [44, 45].
In the early nineties Cook et al found linkage to the
8q24.11-q24.13 region in Multiple Osteochondroma
families [46] and two years later the EXT1 gene was
identified by positional cloning [23]. 
The EXT1 gene, composed of 11 exons, spans
approximately 350kb of genomic DNA (Fig. 3) [47]
with a promoter region that has the characteristics of
a house keeping gene [47]. EXT1 mRNA is ubiquitously
expressed and has a coding sequence of 2238 bp [23].
In mouse embryos, high mRNA levels of the EXT1
homologue have been found in the developing limb
buds [48,49]. EXT1 homologues have also been
identified in Drosophila melanogaster (tout-velu, Ttv)
and Caenorhabditis elegans [50, 51]. 
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F Fi ig g. .   2 2. . Mutation spectrum of the EXT1 and EXT2 genes in MO patients described so far [106]H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(4) 165
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E EX XT T2 2
In two large Multiple Osteochondroma pedigrees
not linked to 8q24, linkage was found to a 3 cM
region  located  at  11p11-p12,  excluding  the
pericentrometric region [52, 53]. In 1996, the EXT2
gene was identified by positional cloning by two
groups independently [24, 25].
The EXT2 gene contains 16 exons (Fig. 3) and spans
approximately 108 kb of genomic DNA [51]. The mRNA
consists of approximately 3kb, with a single open reading
frame of 2154 bp in which the C-terminal region shows
high similarity with EXT1 [24, 25]. The mRNA shows
alternative splicing in exon 1a and 1b and is ubiquitously
expressed [24, 25]. Homologues of EXT2 have been
found in mouse (chromosome 2) [51, 54], Drosophila
melanogaster  (sister  of  tout-velu,  sotv)  [55]  and
Caenorhabditis elegans [51].
Like EXT1, EXT2 has been implicated in a contiguous
gene deletion syndrome, Potocki-Shaffer syndrome
(DEFECT11; OMIM 601224), where patients carry 
a deletion of 11p11.2-p12 [56, 57].  Patients with this
syndrome demonstrate multiple osteochondromas,
enlarged parietal foramina (FPP), craniofacial dysostosis
and mental retardation [56, 57].
E EX XT T   f fu un nc ct ti io on n
The gene products of human EXT1 and EXT2 are
endoplasmic reticulum localised type II transmembrane
glycoproteins. In vivo they form a stable hetero-
oligomeric complex that accumulates in the Golgi
apparatus, where it is involved in heparan sulphate
proteoglycan (HSPG) biosynthesis (reviewed by Esko
et al [58]) (Fig. 4). The EXT1/EXT2 complex catalyses
the elongation of the HS chain [59-62], which is
subsequently deacetylated, sulphated and epimerised
resulting in a large spectrum of structural heterogenic
HS chains. The sulphation pattern of HS chains is
critical for binding specific proteins [58]. Several
growth factors have conserved patterns of basic amino
acids for binding to HSPGs, which is crucial for proper
signalling [63, 64].  
H He ep pa ar ra an n   S Su ul lp ph ha at te e   P Pr ro ot te eo og gl ly yc ca an ns s   ( (H HS SP PG G) )
HSPGs are large multifunctional macromolecules
involved in several growth signalling pathways,
anchorage  to  the  extracellular  matrix  and
sequestering of growth factors (reviewed by Knudson
[65]). Four HSPG families have been identified:
syndecan, glypican, perlecan and CD44 isoforms. 
The syndecan family consists of four members,
encoding  type  I  transmembrane  polypeptides
involved in the anchorage of cells to the extracellular
matrix and binding of growth factors [66]. In mouse
and chick, syndecan-2 and -3 have shown to be
involved in signalling pathways in proliferating
chondrocytes [67-70].
The six glypican family members encode proteins
attached to the cell membrane with a glycosylphosphati-
dylinositol (GPI)-anchor. They predominantly function
as co-receptors [66]. Expression of several glypicans
has been found in the perichondrium, the developing
limb and mesenchymal tissues of the developing
mouse embryo [71].
The largest HSPG, perlecan, is the most common
proteoglycan  of  the  basement  membrane.  It  is
expressed in hyaline cartilage and in all zones of the
rat growth plate during endochondral ossification
[72]. Perlecan, syndecan and glypican are reported
to be involved in FGF-signalling [65, 66].
F Fi ig g. .   3 3. .   Genomic DNA structures of the EXT1 and EXT2 genesH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(4) 166
The fourth HSPG family is specific isoforms of
the type I transmembrane glycoproteins CD44.
The CD44 gene consists of 20 exons of which 10
(so-called variable exons) can be alternatively
spliced (reviewed by Ponta et al [73]). CD44
isoforms containing variable exon 3 (v3) have
been shown to bind growth factors through HS
side chains, thereby regulating cell growth and
motility [74].
In Drosophila, the EXT1 homologue Ttv (tout-velu),
also involved in HS synthesis, is required for the
diffusion of Hedgehog (Hh), an important segment
polarity protein (homologue of mammalian IHh) [50].
Remarkably, in Ttv mutants only the IHh signalling is
affected, while other HSPG-dependent pathways, like
FGF and WNT signalling, are not. This indicates 
a specificity in the regulation of the distribution of
extracellular signals by HSPGs in Drosophila [75, 76]. 
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F Fi ig g. .   4 4. .   The mode of action of the EXT-proteins in heparan sulphate biosynthesis 
After a tetrasaccharide linker is synthesised on conserved serine residues of the core protein, EXTL2 and/or EXTL3 initiate the polymerisation
of the heparan sulphate chain by the addition of N-acetylglucosamine [60, 107]. The EXT1/EXT2 complex subsequently catalyses further
elongation of the heparan sulphate chain by adding alternating units of N-acetylglucosamine and glucuronic acid [59-62]. Subsequent
deacetylation and sulphation of most N-acetylglucosamines, epimerisation of the glucoronic into iduronic acid and further sulphation result
in a large spectrum of structural heterogenic heparan sulphate chains [58, 108].
Adapted from Couchman et al [109] and Nybakken et al [110].H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(4) 167
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G Gr ro ow wt th h   S Si ig gn na al ll li in ng g
I In nd di ia an n  H He ed dg ge eh ho og g  ( (I IH Hh h) )/ /P PT TH Hr rP P  s si ig gn na al ll li in ng g  i in n  t th he e  g gr ro ow wt th h  p pl la at te e
In the growth plate EXT1 and EXT2 are expressed in
the proliferative and transition zone [77] (Fig. 5). The
HSPGs, expressed in all zones of the growth plate [67-
72], are presumed to be involved in the diffusion of IHh
to its receptor in the perichondrium. During normal
embryonic growth IHh, expressed in the transition zone,
is involved in a paracrine feedback loop regulating
proliferation and differentiation of chondrocytes and bony
collar formation in the growth plate (Fig. 5A). In this
feedback loop PTHrP regulates chondrocyte differentiation
by delaying progression of chondrocytes towards the
hypertrophic zone, allowing longitudinal bone growth
[78]. In the rat post-natal growth plate the feedback loop
is confined to the growth plate itself (Fig. 5B), in particular
to the transition zone [79]. 
F Fi ib br ro ob bl la as st t  G Gr ro ow wt th h  F Fa ac ct to or r  ( (F FG GF F) )  s si ig gn na al ll li in ng g  i in n  t th he e  g gr ro ow wt th h  p pl la at te e
The  FGF-signalling  pathway  is  dependent  on
HSPGs for the high affinity binding capacity of the FGF
receptor (FGFR), allowing receptor dimerisation and
subsequent cell signalling [80, 81]. The most potent
mitogen for chondrocytes, FGF-2 (basic FGF), inhibits
differentiation  of  chondrocytes  via  stimulation  of
extracellular matrix synthesis [82, 83]. In contrast,
activation of FGFR3 in the proliferative zone (Fig. 5),
by FGF18 [84] inhibits chondrocyte proliferation via
phosphorylation  of  STAT-1  and  subsequent
upregulation of p21
WAF/CIP1, which can inhibit the cell
cycle [85]. FGFR3 activation also leads to repression
of IHh signalling [80, 81, 86].
H Hi is st to og ge en ne es si is s    a an nd d    s se ec co on nd da ar ry y    s sa ar rc co om ma a
f fo or rm ma at ti io on n
In  the  past,  many  have  considered  the
histogenesis of osteochondroma as a perversion in
the direction of normal bone growth resulting from
aberrant epiphyseal development with displacement
of epiphyseal cartilage. However, several research
groups have demonstrated using different techniques
that both sporadic and hereditary osteochondromas
are true neoplasms [31, 87, 88], resulting in a multi-
step genetic model for peripheral cartilaginous
tumorigenesis (Fig. 6) [89].
F Fi ig g. .   5 5. .   Growth plate signalling 
EXT1 and EXT2 are expressed in the proliferative and transition zone [77] (Fig. 5). The HSPGs, expressed in all zones of the growth plate
[67-72]. A. In the embryonic growth plate chondrocytes in the transition zone secrete IHh protein, which diffuses to its receptor Patched
(Ptc) in the lateral perichondrium. Subsequently, via a yet incompletely understood mechanism, increased secretion of ParaThyroid Hormone
related Protein (PTHrP , PTHlP) is induced at the apical perichondrium, which diffuses to its receptor expressed in the late proliferating
chondrocytes [80]. Terminal differentiation is inhibited by direct or indirect upregulation of Bcl-2, prolonging cell survival [78]. In this way,
PTHrP regulates chondrocyte differentiation by delaying the progression of chondrocytes towards the hypertrophic zone and allowing
longitudinal bone growth. B. In the post-natal growth plate the signalling is confined to the growth plate [79]..
Although some believe that the severity of the
angular deformity is correlated with the number of
sessile osteochondromas [37], several studies in mice
have shown that haploinsufficiency of EXT1 or EXT2
causes severe skeletal deformities [90, 91]. Loss of
the remaining wild-type allele of EXT1 in hereditary
osteochondromas [31] indicated that inactivation of
both copies of the EXT1 gene in cartilaginous cells
of the growth plate is required for osteochondroma
formation, thereby acting as a tumour suppressor
gene [31]. Two studies have shown diminished HSPG
expression in either osteochondromas or cultured
EXT1
-/- cells [92, 93]. This is hypothesised to affect
the  negative  feedback  loop  by  disturbing  IHh
diffusion to Ptc and by preventing high-affinity
binding  of  FGF  to  its  receptor  (Fig.  5).
Immunohistochemical studies have already shown
that  molecules  involved  in  the  IHh/PTHrP  and
FGF/FGFR signalling (PTHrP , PTHrP-R1, Bcl-2, FGF2,
FGFR1,  FGFR3  and  p21)  are  absent  in
osteochondromas  [94]  suggesting  that  growth
signalling is indeed disturbed in osteochondroma. 
At the protein level, re-expression of several of
these signalling molecules (FGF2, FGFR1, p21,
PTHrP and Bcl-2) was found in secondary peripheral
chondrosarcoma and the expression increased with
increasing histological grade [94]. Upregulation of
Bcl-2 characterised malignant transformation of
osteochondroma  towards  grade  I  secondary
peripheral chondrosarcoma [94]. Signalling may now
occur in an autocrine fashion or in a paracrine one
in which IHh acts on cells in its near vicinity, having
to diffuse over only a few cell diameters and thereby
avoiding HSPG-dependent diffusion [94].
The  process  of  malignant  transformation  is
genetically represented by chromosomal instability [95],
probably caused by defects in spindle formation. The
LOH found in osteochondroma was restricted to 8q24
[31], whereas in secondary peripheral chondrosarcomas
LOH was found in virtually all loci tested [95]. Also a
Liesbeth Hameetman et al
F Fi ig g. .   6 6. .   Peripheral Cartilaginous Tumorigenesis
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broad range in DNA ploidy including near-haploidy
and non-specific chromosomal alterations were found
[95, 96]. DNA-flow cytometry of the cartilaginous cap
of osteochondromas showed mild aneuploidy [31],
whereas more severe aneuploidy [97-99], including
near-haploidy [95], was seen in grade I secondary
peripheral chondrosarcomas. 
Further progression towards high-grade secondary
peripheral  chondrosarcomas  is  characterised  by
polyploidisation, which is thought to be evolved from
near-haploid precursor clones [89], and overexpression
of p53 [95].
Near-haploidy was not found in osteochondromas
[87, 88] or in high grade peripheral chondrosarcomas
[95] and can be considered a progression marker
towards a low malignant phenotype [89].  
P Pa at ti ie en nt t   m ma an na ag ge em me en nt t
D Di ia ag gn no os si is s
With the identification of EXT1 and EXT2 as the
genes causative of Multiple Osteochondromas, it has
become possible to screen patients with multiple lesions
for germline mutations in either EXT gene in a diagnostic
setting. However this procedure is time consuming and
costly and therefore it is important to select patients
carefully  on  the  basis  of  family  history,  radiologic
documentation and, if available, review of histology of
resected lesions.
The diagnosis of Multiple Osteochondromas is based
on the combination of two or more radiologically
documented osteochondromas originating from the juxta-
metaphyseal region of the long bones [2, 4], with or
without a positive family history. Radiologically, Multiple
Osteochondroma patients have a typical phenotype, easy
to recognise by the expert eye. This can exclude the
differential diagnoses of other skeletal disorders like
metachondromatosis [100, 101], dysplasia epiphysealis
hemimelica [102, 103] or non-hereditary syndromes that
occur in multiple bones such as enchondromatosis
(Ollier’s disease) [102, 104]. Given the specific radiologic
and histological expertise needed, it is recommended to
seek for an expert opinion from a bone tumour specialist
or from a national bone tumour registry consisting of
clinicians, radiologists and pathologists, before screening
for germline mutations. 
If the typical Multiple Osteochondroma radiologic
phenotype is present, it is important to evaluate the
patient’s family history to see whether other relatives are
(possibly) affected. From these family members radiologic
studies and, if available, histology of resected lesions can
be examined. If there are other affected family members,
Multiple Osteochondromas can be clinically established. 
Then subsequent EXT mutation analysis is optional.
However it can be useful to screen for germline mutations
in family members presenting a mild or no phenotype
and this will also give insight into the inheritance pattern
(penetrance) of the specific mutation. A known EXT
mutation can also be used for prenatal diagnostics. If
there  is  no  positive  family  history,  Multiple
Osteochondromas cannot be excluded, since it is possible
that  the  patient  is  the  founder  of  a  new  Multiple
Osteochondroma family and these index patients should
be screened for EXT mutations.
Mutation  analysis  for  EXT1 and  EXT2 can  be
performed on peripheral blood of the patient. This can
be established through PCR and subsequent sequencing
of all exons of EXT1 and EXT2 [30] and/or two-colour
multiplex ligation-dependent probe amplification (MLPA)
[105]. When a mutation in either gene is found, the
Multiple Osteochondromas diagnosis can be confirmed.
If  there  is  no  mutation  the  diagnosis  of  Multiple
Osteochondromas cannot be excluded, since there is 
a small possibility that the mutation could not be detected
due to technical limitations. With the currently used
methods it is possible to detect point mutations or gross
deletions in 75-88% of the Multiple Osteochondroma
patients [105]. These methods cannot detect positional
changes, like translocations, inversions, insertions or
transpositions. These changes affect the structure of the
gene without changing the sequence or dosage of exons. 
F Fo ol ll lo ow w- -u up p
When the diagnosis of Multiple Osteochondromas is
established, patients should have a regular follow-up to
discover potential malignant transformation at an early
stage and enable adequate treatment to be implemented.
To our knowledge, the literature does not mention a
specific clinical and/or radiologic consensus about the
most proper method for the follow-up of patients with
proven  Multiple  Osteochondromas.  The  following
pathways for both clinical and radiologic follow-up can
be  followed.  Localisation  of  all,  relatively  larger,
osteochondromas can be established with a base-line
bone scan, which shows increased bone activity within
the skeleton at sites of increased bone turnover, like at
the sites of osteochondromas, but also at the epiphysis
and apophyses of growing bones. Since secondary
peripheral chondrosarcomas are extremely rare before
puberty, this is, therefore, only recommended for patients
who have reached skeletal maturation. Regular follow-
up before that time is not necessary unless the patient
presents  with  clinical  complaints.  A  number  of
osteochondromas will demonstrate a normal uptake of
the  radiopharmacon,  demonstrating  complete
maturation, while others may still show an increased
activity of the radiopharmacon. This finding, at the base-
line,  does  not  immediately  and  specifically  imply
malignant transformation, but can well be explained by,H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(4) 170
as yet, incomplete maturation of the osteochondroma or
just by its distinct size. Furthermore, base-line plain
radiographic  examinations  of  areas  that  are  not
accessible to palpation, like the chest, pelvis and scapula
are recommended, because in these areas of the body
late  detection  of  malignant  transformation  of  an
osteochondroma towards peripheral chondrosarcoma
is most common.
After these base-line examinations, patients with
Multiple Osteochondromas could routinely be seen,
each year or every two years, in the outpatient clinic
for clinical and radiologic follow-up. It should be
emphasised to the patients to come at an earlier time
if changes in their clinical condition occur, such as pain
or growth of a known lesion. It is also important to
realise that no new osteochondromas develop after
skeletal maturation. 
Radiologic follow-up could consist of both plain
radiographs of the pelvis, chest and scapulae in
combination with follow-up bone scans. Changes in
the clinical history and findings, in combination with
changes on the plain radiographs or bone scans,
should be regarded with suspicion. As to changes in
the uptake of the radiopharmacon on bone scans
however, it should be considered that increase of the
uptake  does  not  always  indicate  malignant
transformation. It can also be a result of trauma or the
formation of an overlying bursa or inflammatory
reaction. Nevertheless, these changes warrant further
examination through plain radiographs and dedicated
magnetic resonance (MR) imaging, including contrast-
enhanced MR sequences. Also the thickness of the
cartilage cap can be monitored with MR imaging. 
Radiologic skeletal surveys, as a means of follow-up,
do not seem to be of additional value. The role of
ultrasound, in the follow-up of lesions, is still controversial
and needs further studies. 
The entire purpose of adequate follow-up is aimed
at the early detection of malignant transformation,
which enables adequate surgical treatment consisting
of en-bloc resection of the lesion and its pseudo-
capsule with tumour-free margins, preferably in an
oncology centre with experience in treating bone
sarcomas. Inadequate primary surgery of a secondary
peripheral chondrosarcoma will inevitably result in
recurrences and can eventually result in the death
caused by local problems or even metastases.
The process of making a Multiple Osteochondroma
diagnosis and patient follow-up is summarized in 
a flowchart (Fig. 7).
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region of long bones
expert review of
histology+radiology 
to confirm diagnosis
EXT mutation
analysis on
peripheral blond
diagnosis: Multiple
Osteochondromas
consider EXT mutation
analysis of index patients and
positive family member
EXT mutation
analysis on
peripheral blood
no EXT mutation
EXT mutation not confirmed
solitary
osteochondroma
solitary
osteochondroma
watch out for
changes in
clinical condition
consider surgery
at bone sarcoma
centre
growing lesions:
dedicated MRI
radiograph + bone scan
non-accessible sites:
every (other) year
watch out for
changes in
clinical condition
localisation all lesions:
bone scan after skeletal
maturation
family
history
positive
positive
negative
negative
negative
positive optional
confirmed
probably non-hereditary
osteochondromas
diagnosis: Multiple
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history
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C Co on nc cl lu us si io on n
With all new developments and discoveries in the
genetic,  pathological  and  radiologic  behaviour  of
osteochondromas  and  secondary  peripheral
chondrosarcomas, it has become possible to screen and
carefully monitor Multiple Osteochondroma patients and
their families. This will enable us to provide patients with
more adequate care and treatment strategies. 
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